pay for delay
FTC Chairwoman Ramirez Testifies Before House Judiciary Subcommittee on Agency’s Enforcement of U.S. Antitrust Laws to Promote Competition and Protect Consumers
Type: Press ReleaseIn testimony presented to a U.S. House of Representatives Judiciary subcommittee the Federal Trade Commission described its ongoing efforts to protect competition and consumers in many important sectors of the economy, including health care, pharmaceuticals, and technology.
FTC Submits Proposed Amicus Brief Concerning “No-Authorized-Generic” Commitments in Drug Companies’ Patent Settlements
Type: Press ReleaseThe Federal Trade Commission has asked the U.S. District Court for the District of New Jersey to accept an amicus brief that addresses the application of the U.S. Supreme Court’s recent ruling in FTC v. Actavis to a patent settlement containing a “no-authorized-generic” commitment.
FTC: Recent Supreme Court Decision Puts Agency in Stronger Position to Protect Consumers From Anticompetitive Pay-for-Delay Drug Settlements
Type: Press ReleaseThe Federal Trade Commission told a Senate Judiciary subcommittee today that it will continue to challenge anticompetitive pay-for-delay court settlements in the pharmaceutical industry, and that the recent U.S. Supreme Court decision in FTC v. Actavis “is an important victory for consumers and a...
Statement of FTC Chairwoman Edith Ramirez on the U.S. Supreme Court's Decision in FTC v. Actavis, Inc.
Type: Press ReleaseFederal Trade Commission Chairwoman Edith Ramirez issued the following statement regarding today's decision by the U.S. Supreme Court in FTC v. Actavis, Inc., which held that pay-for-delay agreements between brand and generic drug companies are subject to antitrust scrutiny.
Type: Press ReleaseFederal Trade Commission Chairwoman Edith Ramirez released the agency’s 2013 Annual Highlights today at the Spring Meeting of the American Bar Association’s Section of Antitrust Law in Washington, D.C., recognizing the FTC’s continued efforts to protect consumers and promote competition.
FTC Study: In FY 2012, Branded Drug Firms Significantly Increased theUse of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market
Type: Press ReleaseIn Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28 to 40, according to a new Federal Trade Commission staff report. The study also found that in...
FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case; FTC Approves Final Rule to Inform Consumers About Deposit Institutions That Lack Federal Deposit Insurance
Type: Press ReleaseFTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case The Federal Trade Commission has filed an amicus brief in the U.S. Court of Appeals for the Second Circuit, recommending that it hold a rehearing before all the judges ("en banc") of the Ciprofloxacin (Cipro) "pay...
Statement by FTC Chairman Jon Leibowitz Regarding Todays Decision by the U.S. Court of Appeals for the Second Circuit in the Ciprofloxacin "Pay-for-Delay" Case
Type: Press ReleaseFederal Trade Commission Chairman Jon Leibowitz issued the following statement regarding today’s decision by the U.S. Court of Appeals for the Second Circuit, which invited the plaintiffs in the Ciprofloxacin drug patent settlement case to seek further review by the full court of appeals because...
Statement by FTC Chairman Jon Leibowitz Regarding Today’s District Court Decision Denying a Motion to Dismiss the Commission’s Pay-For-Delay Case Against Cephalon Inc.
Type: Press ReleaseToday’s decision seems to reflect a growing understanding—first in Congress now in the courts—that brand name drug companies must not be allowed to make pay-offs to their generic competitors to keep low-cost generic drugs off the market. These deals are costing American consumers $3.5 billion a...
Statement by FTC Chairman Jon Leibowitz Regarding Continuing Need for Legislation Banning Illegal Pay-for-Delay Drug Settlements
Type: Press ReleaseThe Federal Trade Commission will continue working on behalf of Americans who are struggling to pay for their health care. According to our economic estimates, consumers would pocket about $3.5 billion a year if these unconscionable deals were stopped and they had earlier access to generic drugs....